Related Experiment Video
Updated: Jun 25, 2026
Tricolor Transgenic Murine Model for Studying Growth Plate Injury
Published on: September 6, 2024
Growth plate cartilage-targeting nanoparticles for pharmacological treatment of hypochondroplasia
Shang-Hui Ye1,2, Lian-Jie Li1,2, Yi-Jiao Wang3,4
1The First Affiliated Hospital of Xiamen University-ICMRS Collaborating Center for Skeletal Stem Cells, Faculty of Medicine and Life Sciences, School of Medicine, Xiamen University, Xiamen, 361102, China.
Insights
A novel nanoplatform effectively delivers drugs to cartilage, improving growth in a hypochondroplasia mouse model. This breakthrough offers new hope for treating short stature caused by this genetic disorder.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Skeletal Biology
Background:
- Hypochondroplasia (HCH) is a genetic disorder causing short stature due to FGFR3 mutations.
- Current treatments offer limited relief because cartilage's structure hinders drug delivery.
- Developing effective drug delivery systems for cartilage is crucial for HCH treatment.
Purpose of the Study:
- To develop a novel nanoplatform for targeted drug delivery to growth plate cartilage.
- To evaluate the efficacy of this nanoplatform in an in vivo model of HCH.
Main Methods:
- Engineered CT-CM-NPs coated with chondrocyte membranes and a collagen II-binding peptide.
- Administered Purmorphamine via CT-CM-NPs to an HCH mouse model.
- Assessed Hedgehog signaling, ciliogenesis, chondrocyte phenotype, and bone growth.
Main Results:
- CT-CM-NPs demonstrated efficient cartilage targeting and penetration.
- Hedgehog pathway activation and ciliogenesis were restored.
- Significant increases in bone and body length were observed in treated mice.
Conclusions:
- CT-CM-NPs represent a promising nanoplatform for HCH treatment.
- This approach overcomes drug delivery limitations in avascular cartilage.
- The findings suggest potential for clinical translation in treating skeletal dysplasias.
Abstract:
Hypochondroplasia (HCH) is a systemic cartilage disorder caused by gain-of-function mutations in FGFR3, resulting in overactivation of signaling and short stature. Pharmacological therapy remains the primary treatment but provides only partial symptomatic relief, as the avascular and alymphatic nature of growth plate cartilage severely limits drug delivery and accumulation. To address this challenge, we developed CT-CM-NPs, a drug delivery system coated with primary chondrocyte membranes and further modified with the collagen II-binding peptide WYRGRL. This design retains the inherent biological properties of native membranes while incorporating targeting capability, enabling efficient cartilage targeting and penetration. In vivo, CT-CM-NPs effectively delivered the Hedgehog pathway agonist Purmorphamine to the growth plate cartilage in an HCH mouse model, resulting in upregulated Hedgehog signaling, restored impaired ciliogenesis, improved chondrocyte phenotypes, and ultimately increased bone and body length. Collectively, these findings establish CT-CM-NPs as a promising and potentially translatable nanoplatform for the treatment of HCH.
Related Concept Videos
01:27Growth of Cartilage and Bone Tissue
01:24Bone Formation by Endochondral Ossification